However, the combined effects of PAX3 inhibition and chemotherapeutic drugs were tested only in MYCN-non-amplified neuroblastoma cells in this study, and MYCN is frequently amplified in advanced stage neuroblastomas with chemotherapy resistance. The gene discussed is PAX3; the disease is neuroblastoma.